Abstract
In recent years, a clear trend has been observed for taxanes to be used earlier in the course of breast cancer, with a large proportion of patients previously treated with anthracyclines and/or taxanes in the (neo)adjuvant setting. In addition, tolerability issues associated with taxane use in elderly patients and patients with substantial comorbidity, means that taxane use is frequently compromised in a substantial proportion of patients with metastatic breast cancer (MBC). Retreatment with taxanes yields variable results, and alternative cytotoxic agents with good activity in patients with anthracycline- and taxane-pretreated MBC are required. Large studies and meta-analyses have helped to establish the role of anthracycline- and taxane-based adjuvant therapy for early breast cancer (EBC). Addition of further cytotoxic agents has generally met with little success, thus the focus has moved towards optimization of adjuvant therapy through scheduling and patient selection. This review considers recent and ongoing developments in the chemotherapeutic management of EBC and MBC.
Keywords: Anthracyclines, capecitabine, chemotherapy, early breast cancer, metastatic breast cancer, taxanes.
Current Cancer Therapy Reviews
Title:Going Beyond Anthracyclines and Taxanes in Breast Cancer – What’s Next?
Volume: 9 Issue: 1
Author(s): Sunil Verma
Affiliation:
Keywords: Anthracyclines, capecitabine, chemotherapy, early breast cancer, metastatic breast cancer, taxanes.
Abstract: In recent years, a clear trend has been observed for taxanes to be used earlier in the course of breast cancer, with a large proportion of patients previously treated with anthracyclines and/or taxanes in the (neo)adjuvant setting. In addition, tolerability issues associated with taxane use in elderly patients and patients with substantial comorbidity, means that taxane use is frequently compromised in a substantial proportion of patients with metastatic breast cancer (MBC). Retreatment with taxanes yields variable results, and alternative cytotoxic agents with good activity in patients with anthracycline- and taxane-pretreated MBC are required. Large studies and meta-analyses have helped to establish the role of anthracycline- and taxane-based adjuvant therapy for early breast cancer (EBC). Addition of further cytotoxic agents has generally met with little success, thus the focus has moved towards optimization of adjuvant therapy through scheduling and patient selection. This review considers recent and ongoing developments in the chemotherapeutic management of EBC and MBC.
Export Options
About this article
Cite this article as:
Verma Sunil, Going Beyond Anthracyclines and Taxanes in Breast Cancer – What’s Next?, Current Cancer Therapy Reviews 2013; 9 (1) . https://dx.doi.org/10.2174/1573394711309010005
DOI https://dx.doi.org/10.2174/1573394711309010005 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CD24, A Review of its Role in Tumor Diagnosis, Progression and Therapy
Current Gene Therapy Recent Advances for the Synthesis of Selenium-containing Small Molecules as Potent Antitumor Agents
Current Medicinal Chemistry New Advances in Infant Feeding: New Products and Novel Technologies
Recent Patents on Food, Nutrition & Agriculture Thieno[2,3-<i>d</i>]pyrimidin-4(3<i>H</i>)-one Derivatives of Benzimidazole as Potential Anti- Breast Cancer (MDA-MB-231, MCF-7) Agents
Anti-Cancer Agents in Medicinal Chemistry Bioengineered 3D Scaffolds in Cancer Research: Focus on Epithelial to Mesenchymal Transition and Drug Screening
Current Pharmaceutical Design Nitric Oxide Control of Proliferation in Nerve Cells and in Tumor Cells of Nervous Origin
Current Pharmaceutical Design An update on Anti-inflammatory Compounds: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Graphene Oxide-Based Nanocarriers for Cancer Imaging and Drug Delivery
Current Pharmaceutical Design Quinoline as a Privileged Scaffold in Cancer Drug Discovery
Current Medicinal Chemistry Recent Patents of microRNAs as Biomarkers for Breast, Leukemia, Prostate and Cervical Cancers
Recent Patents on Biomarkers Non-Analgesic Effects of Opioids: Opioids and the Endocrine System
Current Pharmaceutical Design Recapitulation of Cancer Nanotherapeutics
Current Nanomedicine DNA-Damaging Anticancer Drugs – A Perspective for DNA Repair- Oriented Therapy
Current Medicinal Chemistry Role of COL4A1 in Basement-Membrane Integrity and Cerebral Small-Vessel Disease. The COL4A1 Stroke Syndrome
Current Medicinal Chemistry DNA Methylation Biomarkers in Serum for Gastric Cancer Screening
Mini-Reviews in Medicinal Chemistry Evidence for Complex Binding Profiles and Species Differences at the Translocator Protein (TSPO) (18 kDa)
Current Molecular Medicine ABC Multidrug Transporters: Target for Modulation of Drug Pharmacokinetics and Drug-Drug Interactions
Current Drug Targets Pathways Related to the Anti-Cancer Effects of Metabolites Derived from Cerrado Biome Native Plants: An Update and Bioinformatics Analysis on Oral Squamous Cell Carcinoma
Protein & Peptide Letters Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment
Anti-Cancer Agents in Medicinal Chemistry Vascular Endothelial Growth Factor Receptor 1, a Therapeutic Target in Cancer, Inflammation and Other Disorders
Current Medicinal Chemistry